Frequently Asked Questions

1What does Caladrius do?
Caladrius Biosciences, Inc., through its subsidiary, PCT, is a leading development and manufacturing partner to the cell therapy industry. PCT works with its clients to overcome the fundamental challenges of cell therapy manufacturing by providing a wide range of innovative services including product and process development, GMP manufacturing, engineering and automation, cell and tissue processing, logistics, storage and distribution, as well as expert consulting and regulatory support. PCT and Hitachi Chemical Co. have entered into a strategic global collaboration to accelerate the creation of a global commercial cell therapy development and manufacturing enterprise with deep engineering expertise. Around the core expertise of PCT, Caladrius strategically develops select product candidates, which currently includes an innovative therapy for type 1 diabetes based on a proprietary platform technology for immunomodulation. See our ‘About Us’ page for more information.
2How many employees does Caladrius Biosciences have?
As of December 31, 2015, the company, including its subsidiaries, had 221 full-time employees.
3Where can I find Caladrius Biosciences’ latest investor presentation?
The company’s most recent investor presentation is available in the “Investors” section on the company’s website.
4What is Caladrius’ ticker symbol, exchange and CUSIP?
The Company’s common stock is traded on NASDAQ, ticker symbol CLBS. The CUSIP for the common stock is 128058104.
5What is Caladrius’ fiscal year?
Caladrius’ fiscal year ends on December 31.
6Where are Caladrius Biosciences’ headquarters?
Caladrius Biosciences Headquarters 106 Allen Road, 4th Floor Basking Ridge, NJ 07920 Tel: (908) 842-0100
7Who is Caladrius’ IR contact?
Lippert/Heilshorn & Associates
Anne Marie Fields
Phone: +1-212-838-3777
E-mail: afields@lhai.com
8What is Caladrius’ Financial Conflict of Interest Policy?
You can view the Company’s Financial Conflict of Interest Policy by clicking here.
9What is Caladrius’ relationship with PCT?
PCT, a Caladrius Company, is a wholly-owned subsidiary of Caladrius Biosciences. Caladrius acquired PCT in January 2011.
10Who are Caladrius’ auditor and corporate legal counsel?
Caladrius’ auditor is Grant Thornton LLP. (www.granthornton.com) Caladrius’ corporate legal counsel is Paul Hastings LLP. (www.paulhastings.com)
11Who is Caladrius’ transfer agent?
Caladrius’ transfer agent is Continental Stock Transfer & Trust Company (www.continentalstock.com) 17 Battery Place, 8th Floor New York NY 10004 Tel: (212) 509-4000
12Who do I contact about replacement of stock certificates?
To replace lost stock certificates, please contact Caladrius Biosciences’ transfer agent
13Who should shareholders notify of a change in address?
To change your address, please contact Caladrius Biosciences’ transfer agent.
14What financial analysts cover Caladrius Biosciences?
15When will Caladrius Biosciences next report financial results?
The company expects to report the financial results for the fourth quarter and fiscal year 2015 in late February/early March 2016.
16Can I buy Caladrius Biosciences stock directly from the company?
Caladrius does not offer a direct stock purchase plan. Shares of the company can be purchased through a brokerage company.
17Does Caladrius Biosciences issue dividends on its common stock?
Caladrius Biosciences has never declared or paid cash dividends. The company intends to retain any future earnings for the operation and expansion of its business and does not anticipate paying any cash dividends in the foreseeable future.
18When is Caladrius Biosciences’ Annual Meeting of Stockholders?
The date and location will be published in the company’s proxy statement, which can be found on the “SEC Filings” section in the “Investors” section on the company’s website.
19What should I do if I have a question that is not answered here?
20Where can I find more information on the reverse stock split effective July 27, 2016?
The reverse stock split is announced at http://www.caladrius.com/press-release/1-for-10-reverse-split/ . Additional information about the reverse stock split can be found in the Company’s Definitive Proxy Statement filed with the Securities and Exchange Commission (SEC) on May 10, 2016, a copy of which is available at www.sec.gov or at the company’s website at www.caladrius.com. More detailed information regarding this reverse stock split can be found in the Company’s Form 8-K filed with the SEC on July 27, 2016.